Abstract
Nafazatrom, a synthetic pyrazolinone derivative, has been shown to have substantial antitumor activity in vitro and antitumor and antimetastatic activity in experimental animal systems. The drug has produced no substantial toxicity in preclinical studies and during limited human trials. A phase I clinical trial with this substance was performed at this institution. Nafazatrom was administered orally in a single daily dose. The initial starting dose was 30 mg/m2 and, in the absence of toxicity, subsequent dose levels were reached after 100% escalation. Six patients were treated at each dose level. Forty-eight patients with various metastatic malignant tumors (mostly with melanoma, breast carcinoma, soft tissue sarcoma, renal cell carcinoma and colorectal carcinoma) were entered on this program. No objective remissions were observed. Twelve patients remained stable for periods in excess of 8 weeks. No consistent, substantial or dose-limiting toxicity was detected. The maximum tolerated dose was not reached, and dose escalation was stopped at 4,000 mg/m2/day as initially planned. With the oral preparation, within this dose range and at this schedule, nafazatrom has no antitumor or other biologic activity.
Similar content being viewed by others
References
Seuter F, Busse WD, Meng K, Hoffmeister F, Moller E, Horstmann H: The antithrombotic activity of BAY g 6575 (nafazatrom). Arzneim-Forsch/Drug Res 29(1):54–59, 1979
Philipp E, Ritter W, Patzschke K: The relationship between dose, pharmacokinetics, plasma concentrations, and antithrombotic effects of nafazatrom. Thromb Res, 1985 (in press)
Vermylen J, Chalmone D, Verstraete M: Stimulation of prostacyclin release from vessel wall by BAY g 6575, an antithrombotic compound. Lancet 1:518–520, 1979
Honn KV: Prostacyclin/thromboxane ratios in tumor growth and metastasis. In: Powles TJ, Bockman RS, Honn KV, Ramwell P (eds): Prostaglandins and Cancer: First International Conference. Alan R. Liss, Inc., New York, 1982, pp 733–752
Baker L, Haas C, Young J et al.: Human in vivo and in vitro evaluation of nafazatrom (NFZ). (Abstract) Proc Am Assoc Cancer Res 24:135, 1983
Urquilla PR: Investigators brochure, BAY g 6575, an antithrombotic agent. Miles Pharmaceuticals, January, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hortobagyi, G.N., Papadoupoulos, N.E., Frye, D. et al. Phase I clinical study of nafazatrom. Invest New Drugs 4, 251–255 (1986). https://doi.org/10.1007/BF00179592
Issue Date:
DOI: https://doi.org/10.1007/BF00179592